Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CS-101 in Acute Chest Syndrome: NCT06565026 Clinical Landscape Report 2026
18 September 2026
NCT06565026 clinical landscape for Acute Chest Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxycarbamide in Anemia, Sickle Cell: NCT06578507 Clinical Landscape Report 2026
18 September 2026
NCT06578507 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ketorolac Tromethamine in Vaso-occlusive crisis: NCT06579703 Clinical Landscape Report 2026
18 September 2026
NCT06579703 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gefurulimab in Myasthenia Gravis: NCT06607627 Clinical Landscape Report 2026
18 September 2026
NCT06607627 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etavopivat in Thalassemia: NCT06609226 Clinical Landscape Report 2026
18 September 2026
NCT06609226 clinical landscape for Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etavopivat in Thalassemia: NCT06581627 Clinical Landscape Report 2026
18 September 2026
NCT06581627 clinical landscape for Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etavopivat in Anemia, Sickle Cell: NCT06612268 Clinical Landscape Report 2026
18 September 2026
NCT06612268 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anitocabtagene autoleucel in Myasthenia Gravis: NCT06626919 Clinical Landscape Report 2026
18 September 2026
NCT06626919 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Azercabtagene Zapreleucel in Multifocal acquired demyelinating sensory and motor neuropathy: NCT06680037 Clinical Landscape Report 2026
18 September 2026
NCT06680037 clinical landscape for Multifocal acquired demyelinating sensory and motor neuropathy: endpoints, sponsor, phase, geography, readouts, asset cont…
9 min read
Blinatumomab in Myasthenia Gravis: NCT06684184 Clinical Landscape Report 2026
18 September 2026
NCT06684184 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Marstacimab-hncq in Hemophilia A: NCT06703606 Clinical Landscape Report 2026
18 September 2026
NCT06703606 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SYS-6020 in Myasthenia Gravis: NCT06688435 Clinical Landscape Report 2026
18 September 2026
NCT06688435 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.